serum and EDTA plasma was good in the IBL assay, but poor in the USCN and Cusabio assays however improved after modifications in the Cusabio assay. Standardization and agreement between assays was poor. Conclusions. The commercially available methods for the measurement of α-Klotho differ in quality. Some of the manufacturers should improve their assays in order to produce accurate results so that reliable conclusions can be drawn from studies in which these assays are used. [2] . In the kidney, α-Klotho is involved in the regulation of both calcium [3] and phosphate handling [4] , while in the vasculature, it inhibits calcification [5] and improves endothelial integrity [6] . There are two forms of the α-Klotho protein, membrane-bound Klotho and secreted Klotho. The extracellular domain of the membrane-bound Klotho is shed and subsequently released in the circulation. As α-Klotho is mainly produced in the kidney, its circulating form has been suggested as a link between renal damage and distant tissue pathology. Importantly, the circulating α-Klotho proteins can be either the shed-product of the ectodomain of the membrane bound form, or a Klotho protein that originates from alternate splicing of the Klotho gene.
Recently, three immunoassays to measure α-Klotho became commercially available. The quality of commercially available immunoassays is not guaranteed (by example shown for FGF23 assays and vitamin D assays [7, 8] ), and therefore, assays should be evaluated carefully. We thus performed an evaluation of commercially available Klotho assays.
S U B J E C T S A N D M E T H O D S
We evaluated the α-Klotho assays of IBL (α-Klotho IBL ; IBL International GmbH, Hamburg, Germany), Cusabio (α-Klotho Cusabio ; Cusabio Biotech, Wuhan, China) and USCN (α-Klotho USCN ; USCN life Science Inc, Wuhan, China). Both Cusabio and USCN do not provide information on the epitopes against which their antibodies are directed in their respective Klotho assays. The IBL assay makes use of the antibodies described by Yamazaki et al. [9] . According to Yamazaki et al. both antibodies specifically recognize a tertiary protein structure of an extracellular domain of αKl. As a consequence, with the IBL assay both forms of circulating Klotho might be measured.
We studied within-run variation, between-run variation, matrix effects, linearity and recovery of added recombinant human Klotho (rhKlotho, Sigma-Aldrich, St Louis, MO, USA) in the three commercially available α-Klotho assays. Analyses were performed according to the instructions of the manufacturers (Table 1) . We used leftover coupled serum and EDTA plasma samples of healthy individuals and patients with chronic kidney disease. Within-run variation (within run % CVs) was calculated from duplicate variation (n = 36-40) using the formula:
whereby ∑ is sum, a and b are the duplicate Klotho concentrations, N is the total number of duplicates and X is the mean [Klotho] of a and b. Between run variation was studied using two samples that were measured every run and calculated as CV% = (standard deviation/mean [Klotho])*100%. Matrix effects were studied by comparing Klotho measured in EDTA plasma and serum, calculated with Pearson's correlation. Recovery of rhKlotho was measured by adding rhKlotho to two serum samples. The amount of the added rhKlotho was chosen based on the concentration range of the respective assay, 20 000 and 40 000 pg in the α-Klotho Cusabio and 200 and 400 pg in the α-Klotho IBL. Recovery was calculated using the following formula:
Recovery% ¼ 
R E S U LT S
Within-and between-run variation is shown in Table 2 .
Within-run variation of the α-Klotho USCN consists of only 18 observations, as the other 18 samples measured were either above or below the range of the standard curve. Impressive differences between EDTA plasma and serum were observed. As we judged the within run variation of the α-Klotho USCN unacceptably high (32%), we did not analyse the other parameters using this assay. Using the α-Klotho Cusabio , about half of the samples measured read above the standard curve. Even more samples were above the standard curve measuring the same samples in a second run. Within-run variation was 13%. The agreement between serum and plasma was poor (R 2 = 0.65; n = 11). Linearity of the α-Klotho Cusabio was moderate, as a 2-, 4-and 8-time dilutions led to values that are 44-80% of expected. Addition of 20 000 and 40 000 pg rhKlotho to serum samples with a basal concentration of 9510 and 8240 pg/mL as measured in the α-Klotho Cusabio , was not detected by the α-Klotho Cusabio .
The within-and between-run variation of the α-Klotho IBL was <5 and <8%, respectively. Measurements in serum and EDTA plasma were in agreement (R 2 = 0.99; n = 20). Linearity was tested by dilution in two samples with a concentration of 1929 and 2864 pg/mL. In one sample, 2-, 4-and 8-time dilutions gave results as expected (100-117% of expected values). However, the 4-and 8-time dilutions in the other sample led to results that were higher than expected (129 and 142%). Undiluted measurements were not possible. Addition of 400 and 200 pg of rhKlotho to serum samples with a basal concentration of 571 and 338 pg/mL as measured with the α-Klotho IBL led to a recovery of 138 and 160%.
D I S C U S S I O N
Standardization of the Klotho assays should improve. All three assays have the same units ( pg/mL), but differ in the concentration range of their standard curves. In addition to the standardization problem that might lead to different absolute values yet a high correlation between assays, the question In order not to have many samples above the standard curve, our protocol changed over the runs, trying to improve the assay. Not more than two runs were determined using the same protocol, therefore no reliable between run CV can be calculated. arises what exactly is measured by these assays. Almost no information is available on the antibodies used in the various assays; thereby, it is not certain which forms of Klotho are detected. Moreover, cross reactivity with other analytes cannot be excluded. A comparison of 20 samples measured using both α-Klotho IBL and α-Klotho Cusabio led to a correlation between these assays of R 2 = 0.003, neither serum nor EDTA plasma correlated between assays.
Recently, Devaraj et al. [10] published an evaluation of the α-Klotho Cusabio , using three modifications to improve the performance of this Klotho assay. One of the modifications is a 2000-instead of 200-fold dilution of the samples. Although this seems to improve the assay, with probably less samples reading above the standard curve, such a high dilution step is a design mistake of the manufacturer as it either leads to imprecision or to waste of sample buffer. In the study of Deveraj et al. only serum was tested, without comparison with EDTA plasma. We, therefore, repeated part of our measurements with these modifications. The intra-assay variation of the α-Klotho Cusabio did not improve in our hands (15%, n = 24). However, the agreement between EDTA plasma and serum significantly improved by the additional dilution, R 2 = 0.92 (n = 15).
Despite the above-mentioned important limitations of the current assays, several publications report on results of circulating forms of Klotho in clinical cohorts, as summarized in Table 3 . Some of the inconsistencies between these cohorts might be due to the limitations of the assays used.
In conclusion, the commercially available methods for the measurement of α-Klotho differ in quality. Some of the manufacturers should improve their assays in order to produce accurate results so that reliable conclusions can be drawn from studies in which these assays are used. 
